Wells Fargo
ODT

Wells Fargo’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Wells Fargo’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-216
Closed – – 8363
2021
Q4 		$0 Buy
216
+198
+1,100% +$468 ﹤0.01% 8226
2021
Q3 		$0 Hold
18
– – ﹤0.01% 7868
2021
Q2 		$0 Sell
18
-1,326
-99% -$4.55K ﹤0.01% 7808
2021
Q1 		$4K Sell
1,344
-17,535
-93% -$331K ﹤0.01% 6563
2020
Q4 		$363K Sell
18,879
-2,839
-13% -$43.8K ﹤0.01% 4756
2020
Q3 		$292K Buy
21,718
+2,250
+12% +$63.7K ﹤0.01% 4737
2020
Q2 		$825K Buy
19,468
+5,558
+40% +$180K ﹤0.01% 3967
2020
Q1 		$384K Sell
13,910
-32
-0.2% -$933 ﹤0.01% 4237
2019
Q4 		$453K Sell
13,942
-688
-5% -$21.3K ﹤0.01% 4447
2019
Q3 		$381K Buy
14,630
+11,508
+369% +$385K ﹤0.01% 4558
2019
Q2 		$115K Sell
3,122
-679
-18% -$16.3K ﹤0.01% 5254
2019
Q1 		$84K Sell
3,801
-9
-0.2% -$157 ﹤0.01% 5185
2018
Q4 		$54K Sell
3,810
-25
-0.7% -$389 ﹤0.01% 5493
2018
Q3 		$74K Buy
3,835
+204
+6% +$4.16K ﹤0.01% 5465
2018
Q2 		$80K Sell
3,631
-237
-6% -$5.52K ﹤0.01% 5461
2018
Q1 		$82K Buy
+3,868
New +$91.2K ﹤0.01% 5394

Other funds holding ODT

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Wells Fargo's ODT Position: Q1 2022 in Review

Wells Fargo sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2022, closing a stake of 216 shares.

Wells Fargo first reported a position in ODT in Q1 2018 and held it in 16 quarters. The position peaked at $825K in Q2 2020. 8 funds tracked by Wall St. Rank hold ODT as of Q1 2022.

  • Wells Fargo reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Wells Fargo sold 216 Odonate Therapeutics, Inc. Common Stock shares in Q1 2022.
  • Wells Fargo first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 16 quarters.
  • Wells Fargo's Odonate Therapeutics, Inc. Common Stock position peaked at $825K in Q2 2020.
  • 8 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Wells Fargo's 13F filing for Q1 2022, filed 16 May 2022.